Citius Pharmaceuticals (NASDAQ:CTXR) vs. Galectin Therapeutics (NASDAQ:GALT) Head to Head Comparison

Citius Pharmaceuticals (NASDAQ:CTXR) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk and valuation.

Volatility & Risk

Citius Pharmaceuticals has a beta of 1.05, indicating that its stock price is 5% more volatile than the S&P 500. Comparatively, Galectin Therapeutics has a beta of 0.45, indicating that its stock price is 55% less volatile than the S&P 500.

Valuation & Earnings

This table compares Citius Pharmaceuticals and Galectin Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Pharmaceuticals	N/A	N/A	-$37.43 million	($2.45)	-0.29
Galectin Therapeutics	N/A	N/A	-$30.84 million	($0.48)	-4.77

Galectin Therapeutics is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations for Citius Pharmaceuticals and Galectin Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Pharmaceuticals	1	2	1	0	2.00
Galectin Therapeutics	1	0	1	0	2.00

Citius Pharmaceuticals currently has a consensus price target of $6.00, indicating a potential upside of 744.83%. Galectin Therapeutics has a consensus price target of $11.00, indicating a potential upside of 380.35%. Given Citius Pharmaceuticals’ higher possible upside, equities research analysts clearly believe Citius Pharmaceuticals is more favorable than Galectin Therapeutics.

Institutional and Insider Ownership

16.9% of Citius Pharmaceuticals shares are owned by institutional investors. Comparatively, 11.7% of Galectin Therapeutics shares are owned by institutional investors. 5.0% of Citius Pharmaceuticals shares are owned by insiders. Comparatively, 52.6% of Galectin Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Citius Pharmaceuticals and Galectin Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Citius Pharmaceuticals	N/A	-49.34%	-28.64%
Galectin Therapeutics	N/A	N/A	-214.23%

Summary

Citius Pharmaceuticals beats Galectin Therapeutics on 5 of the 9 factors compared between the two stocks.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

About Galectin Therapeutics

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.